Malignant syndrome in Parkinson's disease: Concept and review of the literature

Parkinsonism and Related Disorders

Volumn 9, Issue SUPPL. 1, 2003, Pages 3-9

  Mizuno, Yoshikuni ^a   Takubo, Hideki ^b   Mizuta, Eiiji ^c   Kuno, Sadako ^c  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO RINKAI HOSPITAL   (Japan)

^c NONE

Author keywords

Levodopa; Levodopa withdrawal; Malignant hyperthermia; Malignant syndrome; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; BROMOCRIPTINE; DANTROLENE; INFUSION FLUID; LEVODOPA;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; AUTONOMIC DYSFUNCTION; CASE REPORT; CLINICAL FEATURE; CONSCIOUSNESS DISORDER; CREATINE KINASE BLOOD LEVEL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; HYPERTHERMIA; INDUCED HYPOTHERMIA; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSON DISEASE; PNEUMONIA; PRIORITY JOURNAL; RIGIDITY;

EID: 0037963038     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(02)00125-6     Document Type: Review

References (56)

1. Toru M., Matsuda O., Makiguchi K., Sugano K. Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. J Nerv Ment Dis. 169:1981;324-327.
2. Fujitake J., Kuno S., Nishitani H. Neuroleptic malignant syndrome-like state in eight patients with parkinsonism. Rinshoshinkeigaku. 24:1984;371-378.
3. Henderson V.W., Wooten G.F. Neuroleptic malignant syndrome. A pathogenetic role for dopamine receptor blockade? Neurology. 31:1981;132-137.
4. Levenson J.L. Neuroleptic malignant syndrome. Am J Psychiatr. 142:1985;1137-1145.
5. Addonizio G., Susman V.L., Roth S.D. Neuroleptic malignant syndrome. Review and analysis of 115 cases. Biol Psychiatr. 22:1987;1004-1020.
6. Sechi G.P., Tanda F., Mutani R. Fatal hyperpyrexia after withdrawal of levodopa. Neurology. 34:1984;249-251.
7. Figa-Talamanca L., Gualandi C., Di Meo L., Di Battista G., Neri G., Lo Russo F. Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause. Neurology. 35:1985;258-261.
8. Friedman J.H., Feinberg S.S., Feldman R.G. A neuroleptic malignant like syndrome due to levodopa therapy withdrawal. JAMA. 15:(254):1985;2792-2795.
9. Gibb W.R., Griffith D.N. Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome. Postgrad Med J. 62:1986;59-60.
10. Di Rosa A.E., Morgante L., Coraci M.A., Crisafulli A., Cacciola G., Di Stetano G., et al. Functional hyperthermia due to central dopaminergic impairment. Funct Neurol. 3:1988;211-215.
11. Rascol O., Salachas F., Montastruc J.L. Neuroleptic malignant-like syndrome following levodopa withdrawal. Rev Neurol (Paris). 146:1990;215-218.
12. Keyser D.L., Rodnitzky R.L. Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy. Arch Intern Med. 151:1991;794-796.
13. Reutens D.C., Harrison W.B., Goldswain P.R. Neuroleptic malignant syndrome complicating levodopa withdrawal. Med J. 155:1991;53-54.
14. Melzer W., Dietze B. Malignant hyperthermia and excitation-contraction coupling. Acta Physiol Scand. 171:2001;367-378.
15. Rubtsov A.M. Molecular mechanisms of regulation of the activity of sarcoplasmic reticulum Ca-release channels (ryanodine receptors), muscle fatigue, and Severin's phenomenon. Biochemistry (Mosc). 66:2001;1132-1143.
16. 2+ sparks in skeletal muscle. Front Biosci. 7:2002;1195-1211.
17. Mickelson J.R., Gallant E.M., Litterer L.A., Johnson K.M., Rempel W.E., Louis C.F. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. J Biol Chem. 263:1988;9310-9315.
18. MacLennan D.H., Duff C., Zorzato F., Fujii J., Phillips M., Korneluk R.G., et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature. 343:1990;559-561.
19. Quane K.A., Keating K.E., Manning B.M., Sandratlealy J.M., Monsieurs K., Heffron J.J.A., et al. Detection of a novel common mutation in the ryanodine receptor gene in the malignant hyperthermia: implications for diagnosis and heterogeneity studies. Hum Mol Genet. 3:1994;471-476.
20. Gronert G.A., Mott J., Lee J. Aetiology of malignant hyperthermia. Br J Anesthet. 60:1988;253-267.
21. Parada M.A., Puig de Parada M., Rada P., Hernandez L. Sulpiride increases and dopamine decreases intracranial temperature in rat when injected in the lateral hypothalamus: an animal model for the neuroleptic malignant syndrome? Brain Res. 674:1995;117-121.
22. Horn E., Lach B., Lapierre Y., Hrdina P. Hypothalamic pathology in the neuroleptic malignant syndrome. Am J Psychiatr. 145:1988;617-620.
23. Martin D., Swash M. Muscle pathology in the neuroleptic malignant syndrome. Am J Psychiatr. 145:1988;617-620.
24. Yamawaki Y., Ogawa N. Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) with disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease. Rinshoshinkeigaku. 31:1991;62-67.
25. Yamawaki Y., Ogawa N. Successful treatment of levodopa-induced neuroleptic malignant syndrome (NMS) and disseminated intravascular coagulation (DIC) in a patient with Parkinson's disease. Intern Med. 31:1992;1298-1302.
26. Gibb W.R. Neuroleptic malignant syndrome in striatonigral degeneration. Br J Psychiatr. 153:1988;254-255.
27. Ueda M., Hamamoto M., Otsubo K., Miyazaki T., Terashi A. Monoamine imbalance of the central nervous system in a case of Shy-Drager syndrome with recurrent attacks of a neuroleptic malignant syndrome. Rinshoshinkeigaku. 36:1996;696-698.
28. Konagaya M., Goto Y., Matsuoka Y., Matsuoka Y., Konishi T. Malignant syndrome in multiple system atrophy. No to Shinkei. 49:1997;516-520.
29. Simpson D.M., Davis G.C. Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine. Am J Psychiatr. 141:1984;796-797.
30. Gordon P.H., Frucht S.J. Neuroleptic malignant syndrome in advanced Parkinson's disease. Mov Disord. 16:2001;960-962.
31. Kuno S., Mizuta E., Yamasaki S. Neuroleptic malignant syndrome in parkinsonian patients: risk factors. Eur Neurol. 38:(Suppl. 2):1997;56-59.
32. Pfeiffer R.F., Sucha E.L. "On-off"-induced lethal hyperthermia. Mov Disord. 4:1989;338-341.
33. Mizuta E., Yamasaki S., Nakatake M., Kuno S. Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period. Neurology. 43:1993;1048-1049.
34. Rupprecht R., Koch M., Montkowski A., Lancel M., Faulhaber J., Harting J., et al. Assessment of neuroleptic-like properties of progesterone. Psychopharmacology (Berl). 143:1999;29-38.
35. Jones E.M., Dawson A. Neuroleptic malignant syndrome: a case report with post-mortem brain and muscle pathology. J Neurol Neurosurg Psychiatr. 52:1989;1006-1009.
36. Kornhuber J., Weller M. Neuroleptic malignant syndrome. Curr Opin Neurol. 7:1994;353-357.
37. Ueda M., Hamamoto M., Nagayama H., Otsubo K., Nito C., Miyazaki T., Terashi A., Katayama Y. Susceptibility to neuroleptic malignant syndrome in Parkinson's disease. Neurology. 52:1999;777-781.
38. Ueda M., Hamamoto M., Nagayama H., Okubo S., Amemiya S., Katayama Y. Biochemical alterations during medication withdrawal in Parkinson's disease with and without neuroleptic malignant-like syndrome. J Neurol Neurosurg Psychiatr. 71:2001;111-113.
39. Nakane S., Motomura M., Furuya T., Shirabe S., Nakamura T. A case of juvenile Parkinson disease with vocal cord abductor paralysis in the course of malignant syndrome. Rinshoshinkeigaku. 39:1999;370-372.
40. Osoegawa M., Motomura S., Yamanaka H., Tamura K., Miyoshi T. A successfully treated parkinsonian patient with neuroleptic malignant syndrome complicated by status epilepticus and disseminated intravascular coagulation. Rinshoshinkeigaku. 39:1999;653-657.
41. Gibb W.R., Lees A.J. The neuroleptic malignant syndrome - a review. Quart J Med. 56:1985;421-429.
42. Olmsted T.R. Neuroleptic malignant syndrome: guidelines for treatment and reinstitution of neuroleptics. South Med J. 81:1988;888-891.
43. Blank J.W., Boggs S.D. Successful treatment of an episode of malignant hyperthermia using a large dose of dantrolene. J Clin Anesthet. 5:1993;69-72.
44. Wang H.C., Hsieh Y. Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy. Mov Disord. 16:2001;765-767.
45. Seki H., Muneta S., Kobayashi T. Malignant syndrome associated with disseminated intravascular coagulation and a high level of amylase in serum, followed by diabetic coma in an elderly patient with Parkinson's disease during L-dopa therapy. Nippon Ronen Igakkai Zasshi. 35:1998;139-144.
46. Pelonero A.L., Levenson J.L., Pandurangi A.K. Neuroleptic malignant syndrome: a review. Psychiatr Serv. 49:1998;1163-1172.
47. Velamoor V.R., Norman R.M., Caroff S.N., Mann S.C., Sullivan K.A., Antelo R.E. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis. 182:1994;168-173.
48. Becker B.N., Ismail N. The neuroleptic malignant syndrome and acute renal failure. J Am Soc Nephrol. 4:1994;1406-1412.
49. Spivak B., Maline D.I., Kozyrev V.N., Mester R., Nedura S.A., Ravilov R.S., et al. Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow. Eur Psychiatr. 15:2000;330-333.
50. Adityanjee, Aderibigbe Y.A., Mathews T. Epidemiology of neuroleptic malignant syndrome. Clin Neuropharmacol. 22:1999;151-158.
51. Miyatake R., Iwahashi K., Matsushita M., Nakamura K., Suwaki H. No association between the neuroleptic malignant syndrome and mutations in the RYR1 gene associated malignant hyperthermia. J Neurol Sci. 143:1996;161-165.
52. Heiman-Patterson T.D. Neuroleptic malignant syndrome and malignant hyperthermia. Important issues for the medical consultant. Med Clin North Am. 77:1993;477-492.
53. Jurkat-Rott K., McCarthy T., Lehmann-Horn F. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve. 23:2000;4-17.
54. McCarthy T.V., Quane K.A., Lynch P.J. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat. 15:2000;410-417.
55. Monnier N., Romero N.B., Lerale J., Landrieu P., Nivoche Y., Fardeav M., et al. Familial and sporadic forms of central core disease are associated with mutations in the C-terminal domain of the skeletal muscle ryanodine receptor. Hum Mol Genet. 10:2001;2581-2592.
56. Romero N.B., Nivoche Y., Lunardi J., Bruneau B., Cheval M.A., Hillaire D., et al. Malignant hyperthermia and central core disease: analysis of two families with heterogeneous clinical expression. Neuromusc Disord. 3:1993;547-551.